{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T07:32:37Z","timestamp":1761291157782,"version":"3.37.3"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T00:00:00Z","timestamp":1727654400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T00:00:00Z","timestamp":1727654400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Bonn"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmologie"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s00347-024-02114-5","type":"journal-article","created":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T08:03:02Z","timestamp":1727683382000},"page":"985-989","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Bilaterale Aderhautamotio und Hypotonie unter Therapie mit Checkpointinhibitoren","Bilateral choroidal detachment and hypotension under treatment with checkpoint inhibitors"],"prefix":"10.1007","volume":"121","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-1515-1863","authenticated-orcid":false,"given":"Jonathan","family":"Meinke","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maike S.","family":"Adamson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marlene","family":"Sa\u00dfmannshausen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Ach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank G.","family":"Holz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias M.","family":"Mauschitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,9,30]]},"reference":[{"issue":"8","key":"2114_CR1","doi-asserted-by":"publisher","first-page":"3041","DOI":"10.1073\/pnas.0711741105","volume":"105","author":"J Tsai","year":"2008","unstructured":"Tsai J et al (2008) Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. PNAS 105(8):3041\u20133046. https:\/\/doi.org\/10.1073\/pnas.0711741105","journal-title":"PNAS"},{"issue":"11","key":"2114_CR2","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.3390\/biom12111562","volume":"12","author":"M Morante","year":"2022","unstructured":"Morante\u00a0M et\u00a0al (2022) Immune Checkpoint Inhibitors and RAS\u2013ERK Pathway-Targeted Drugs as Combined Therapy for the Treatment of Melanoma. Biomolecules 12(11):1562. https:\/\/doi.org\/10.3390\/biom12111562","journal-title":"Biomolecules"},{"key":"2114_CR3","volume-title":"Verdachtsf\u00e4lle Unerw\u00fcnschter Reaktionen Nach Checkpoint-Inhibitoren Aus Deutschland","author":"L Heymans","year":"2016","unstructured":"Heymans\u00a0L, Mentzer\u00a0D, Keller-Stanislawski\u00a0B (2016) Verdachtsf\u00e4lle Unerw\u00fcnschter Reaktionen Nach Checkpoint-Inhibitoren Aus Deutschland"},{"issue":"1","key":"2114_CR4","doi-asserted-by":"publisher","first-page":"14","DOI":"10.2174\/1574886313666180730114309","volume":"14","author":"KM Plachouri","year":"2019","unstructured":"Plachouri\u00a0KM, Vryzaki\u00a0E, Georgiou\u00a0S (2019) Cutaneous Adverse Events of Immune Checkpoint Inhibitors: A\u00a0Summarized Overview. Curr Drug Saf 14(1):14\u201320. https:\/\/doi.org\/10.2174\/1574886313666180730114309","journal-title":"Curr Drug Saf"},{"key":"2114_CR5","doi-asserted-by":"publisher","first-page":"4073","DOI":"10.1200\/JCO.21","volume":"39","author":"BJ Schneider","year":"2021","unstructured":"Schneider\u00a0BJ, Naidoo\u00a0J, Santomasso\u00a0BD et\u00a0al (2021) Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. J\u00a0Clin Oncol 39:4073\u20134126. https:\/\/doi.org\/10.1200\/JCO.21","journal-title":"J Clin Oncol"},{"key":"2114_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/s12348-022-00321-2","author":"A Martens","year":"2023","unstructured":"Martens\u00a0A, Schauwvlieghe\u00a0PP, Madoe\u00a0A, Casteels\u00a0I, Aspeslagh\u00a0S (2023) Ocular adverse events associated with immune checkpoint inhibitors, a\u00a0scoping review. J\u00a0Ophthalmic Inflamm Infect. https:\/\/doi.org\/10.1186\/s12348-022-00321-2","journal-title":"J Ophthalmic Inflamm Infect"},{"issue":"10","key":"2114_CR7","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1001\/jamaophthalmol.2018.1851","volume":"136","author":"LA Acaba-Berrocal","year":"2018","unstructured":"Acaba-Berrocal\u00a0LA, Lucio-Alvarez\u00a0JA, Mashayekhi\u00a0A, Ho\u00a0AC, Dunn\u00a0JP, Shields\u00a0CL (2018) Birdshot-like Chorioretinopathy Associated with Pembrolizumab Treatment. JAMA Ophthalmol 136(10):1205\u20131207. https:\/\/doi.org\/10.1001\/jamaophthalmol.2018.1851","journal-title":"JAMA Ophthalmol"},{"key":"2114_CR8","doi-asserted-by":"crossref","unstructured":"Dalvin LA, Shields CL, Orloff M, Sato T, Shields JA (2018) Review CHECKPOINT INHIBITOR IMMUNE THERAPY Systemic Indications and Ophthalmic Side Effects. Vol 38. http:\/\/journals.lww.com\/retinajournal","DOI":"10.1097\/IAE.0000000000002181"},{"issue":"5","key":"2114_CR9","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/s00347-019-00963-z","volume":"117","author":"N Mihailovic","year":"2020","unstructured":"Mihailovic\u00a0N, Dyballa\u00a0J, Herz\u00a0S et\u00a0al (2020) Vogt-Koyanagi-Harada-like uveitis under immune checkpoint inhibitor treatment for metastasized malignant melanoma. Ophthalmologe 117(5):467\u2013471. https:\/\/doi.org\/10.1007\/s00347-019-00963-z","journal-title":"Ophthalmologe"},{"key":"2114_CR10","first-page":"26","volume-title":"Ver\u00e4nderungen und Risiken neuer immunbasierter Tumortherapien","author":"U Pleyer","year":"2020","unstructured":"Pleyer\u00a0U (2020) Ver\u00e4nderungen und Risiken neuer immunbasierter Tumortherapien. Der Augenspiegel, S\u00a026\u201330"},{"key":"2114_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.701951","author":"L Zhou","year":"2021","unstructured":"Zhou\u00a0L, Wei\u00a0X (2021) Ocular Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors in Lung Cancer. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2021.701951","journal-title":"Front Immunol"},{"issue":"10","key":"2114_CR12","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1001\/jamaoncol.2016.1051","volume":"2","author":"CF Friedman","year":"2016","unstructured":"Friedman\u00a0CF, Proverbs-Singh\u00a0TA, Postow\u00a0MA (2016) Treatment of the Immune-Related Adverse Effects of Immune Checkpoint Inhibitors: A\u00a0Review. JAMA Oncol 2(10):1346\u20131353. https:\/\/doi.org\/10.1001\/jamaoncol.2016.1051","journal-title":"JAMA Oncol"},{"issue":"12","key":"2114_CR13","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","volume":"33","author":"J Haanen","year":"2022","unstructured":"Haanen\u00a0J, Obeid\u00a0M, Spain\u00a0L et\u00a0al (2022) Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 33(12):1217\u20131238. https:\/\/doi.org\/10.1016\/j.annonc.2022.10.001","journal-title":"Ann Oncol"},{"issue":"5","key":"2114_CR14","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1007\/s00347-024-02034-4","volume":"121","author":"D D\u00f6rfel","year":"2024","unstructured":"D\u00f6rfel\u00a0D, Babst\u00a0N, Heindl\u00a0LM, Kakkassery\u00a0V, M\u00fcller\u00a0MR (2024) Staging und Systemtherapie bei okul\u00e4ren und periokul\u00e4ren Metastasen. Ophthalmologie 121(5):374\u2013381. https:\/\/doi.org\/10.1007\/s00347-024-02034-4","journal-title":"Ophthalmologie"}],"container-title":["Die Ophthalmologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-024-02114-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00347-024-02114-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-024-02114-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T15:03:33Z","timestamp":1732892613000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00347-024-02114-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,30]]},"references-count":14,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["2114"],"URL":"https:\/\/doi.org\/10.1007\/s00347-024-02114-5","relation":{},"ISSN":["2731-720X","2731-7218"],"issn-type":[{"type":"print","value":"2731-720X"},{"type":"electronic","value":"2731-7218"}],"subject":[],"published":{"date-parts":[[2024,9,30]]},"assertion":[{"value":"15 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"J.\u00a0Meinke, M.S.\u00a0Adamson, M.\u00a0Sa\u00dfmannshausen, T.\u00a0Ach, F.G.\u00a0Holz und M.M.\u00a0Mauschitz geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien. F\u00fcr Bildmaterial oder anderweitige Angaben innerhalb des Manuskripts, \u00fcber die Patient\/-innen zu identifizieren sind, liegt von ihnen und\/oder ihren gesetzlichen Vertretern\/Vertreterinnen eine schriftliche Einwilligung vor.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}